Acurx shareholders approve reverse split, equity plan increase, and director elections at annual meeting

Acurx Pharmaceuticals, Inc.

All six proposals passed at July 17 meeting; 74.38% of shares represented.
Reverse stock split authorized at ratio 1:10 to 1:30; board to set timing and exact ratio.
2021 Equity Plan share reserve increased from 177,448 to 2,677,448 shares.
Directors Sailer and Harrison re-elected; auditor CohnReznick ratified; warrant exercise and ELOC approved for Nasdaq compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.